Business Context and Reporting Period
Moderna, Inc. filed a Current Report on Form 8-K on July 25, 2020, regarding a material definitive agreement. The company is a biotechnology firm focused on mRNA therapeutics, specifically advancing its vaccine candidate (mRNA-1273) against SARS-CoV-2.
Key Financial Metrics
This filing does not report standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The primary financial data point disclosed is the value of a government contract amendment:
- Contract Value Increase: The maximum award under the BARDA Contract was increased from approximately $483 million to approximately $955 million.
- Contract Extension: The period of performance was extended to August 31, 2023.
Material Changes
The material change reported is the amendment to the contract with the Biomedical Advanced Research and Development Authority (BARDA). This amendment significantly increases the potential funding available to Moderna for clinical studies and manufacturing of its COVID-19 vaccine candidate.
Guidance, Outlook, and Risks
Outlook: The increased funding supports the advancement of mRNA-1273 to potential licensure. Risks and Contingencies: The contract includes standard government provisions, specifically granting the government the right to terminate the contract at any time for its convenience. The filing notes that the description of terms is brief and qualified by the full amendment text to be filed in the subsequent Form 10-Q.
Investor Verification Checklist
- Verify the specific milestones and payment terms within the full BARDA Amendment (to be filed in the Q3 2020 Form 10-Q).
- Confirm the conditions under which the government may terminate the contract for convenience.
- Review the press release dated July 26, 2020 (Exhibit 99.1) for additional context on the agreement.
